Skip to content

Endo Pharmaceuticals adopts new identity

Endo Pharmaceuticals Holdings Inc. is getting a new company name: Endo Health Solutions Inc. The company said Endo Pharmaceuticals stockholders voted in favor of the name change on Wednesday at the annual shareholders meeting.

Table of Contents

CHADDS FORD, Pa. — Endo Pharmaceuticals Holdings Inc. is getting a new company name: Endo Health Solutions Inc.

The company said Endo Pharmaceuticals stockholders voted in favor of the name change on Wednesday at the annual shareholders meeting.

Endo noted that the new name comes with the launch of a new corporate identity that more accurately reflects the company’s new business model. Endo Health Solutions said it has aggregated four operating businesses into one enterprise aimed at delivering integrated, end-to-end solutions — mainly in pain management and urology — for the benefit of providers, payers and patients.

Under the new corporate architecture, Endo Health Solutions will deliver products and services through four operating segments: AMS, a developer of innovative medical devices; Endo Pharmaceuticals, a provider of branded pharmaceuticals; HealthTronics, a provider of medical services, including practice management software, laboratory solutions and medical records technology; and Qualitest, a manufacturer of generic drugs.

Endo explained that its vision is to approach therapeutic areas and disease states as pathways, and to identify, develop and incorporate medical interventions beyond the traditional chemical and biological treatments.

"This important decision by our shareholders marks a milestone in our company’s history," stated Dave Holveck, president and chief executive officer, "and reinforces our position in the market as a leading provider of health solutions, merging health care information and a broader array of innovative treatment options that can ultimately lead to improved health outcomes for patients."

Comments

Latest

FMI: Private brands take hold

FMI: Private brands take hold

Perceptions around private brands have changed; they are no longer seen merely as generics or national brand equivalents, Doug Baker, vice president, industry relations at FMI, said in releasing the report, titled “The Power of Private Brands 2024.”